The LIFT trial: study protocol for a double-blind, randomised, placebo-controlled trial of K(+)-binder Lokelma for maximisation of RAAS inhibition in CKD patients with heart failure

BACKGROUND: CKD is common in heart failure (HF) and associated with morbidity and mortality, yet life-prolonging medications such as renin-angiotensin-aldosterone inhibitors (RAASi) are underused due to risk of hyperkalaemia. Sodium zirconium cyclosilicate (SZC) is a potassium-binding medication tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Murphy, Daniel, Ster, Irina Chis, Kaski, Juan-Carlos, Anderson, Lisa, Banerjee, Debasish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8258742/
https://www.ncbi.nlm.nih.gov/pubmed/34229607
http://dx.doi.org/10.1186/s12882-021-02439-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8258742/
https://www.ncbi.nlm.nih.gov/pubmed/34229607
http://dx.doi.org/10.1186/s12882-021-02439-2

Ejemplares similares